{"id":13636,"date":"2026-10-09T07:00:00","date_gmt":"2026-10-09T05:00:00","guid":{"rendered":"https:\/\/irlab.se\/mfn_news\/irlab-presenterar-pa-redeye-theme-neurology-2\/"},"modified":"2026-10-09T07:00:00","modified_gmt":"2026-10-09T05:00:00","slug":"irlab-presenterar-pa-redeye-theme-neurology-2","status":"publish","type":"mfn_news","link":"https:\/\/irlab.se\/sv\/mfn_news\/irlab-presenterar-pa-redeye-theme-neurology-2\/","title":{"rendered":"IRLAB presenterar p\u00e5 Redeye Theme: Neurology"},"content":{"rendered":"
\n

G\u00f6teborg, den 9 oktober 2026 \u2014 IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), ett bolag som uppt\u00e4cker och utvecklar nya behandlingar f\u00f6r Parkinsons sjukdom, meddelar idag att vd Kristina Torfg\u00e5rd kommer att presentera IRLAB vid Redeye: Theme Neurology den 15 oktober i Stockholm.<\/strong><\/p>\n<\/div>\n

\n

S\u00e5v\u00e4l svenska som internationella investerare deltar i m\u00f6tet, vilket ger bolaget goda m\u00f6jligheter att utvidga sitt n\u00e4tverk och knyta nya kontakter.<\/p>\n

Evenemanget h\u00e5lls p\u00e5 Redeyes kontor, M\u00e4ster Samuelsgatan 42 i Stockholm.
Presentationen kommer \u00e4ven att direkts\u00e4ndas via l\u00e4nken nedan och finnas tillg\u00e4nglig i efterhand p\u00e5 Redeyes hemsida och sociala medier.<\/p>\n

Mer information om m\u00f6tet: https:\/\/www.redeye.se\/events\/1145293\/redeye-theme-neurology-4<\/a><\/p>\n<\/div>\n

\n

F\u00f6r mer information<\/strong><\/p>\n

\n

Kristina Torfg\u00e5rd, VD
Tel: +46 730 60 70 99
E-post: kristina.torfgard@irlab.se<\/a><\/p>\n<\/div>\n

\n

Om IRLAB<\/strong><\/p>\n

\n

IRLAB uppt\u00e4cker och utvecklar en portf\u00f6lj av transformativa behandlingar f\u00f6r alla stadier av Parkinsons sjukdom. Bolaget har sitt ursprung i Nobelpristagaren Prof. Arvid Carlssons forskargrupp och uppt\u00e4ckten av ett samband mellan st\u00f6rningar i hj\u00e4rnans signalsubstanser och hj\u00e4rnans sjukdomar. Mesdopetam (IRL790), under utveckling f\u00f6r behandling av levodopa-inducerade dyskinesier, har slutf\u00f6rt Fas IIb och \u00e4r i f\u00f6rberedelse f\u00f6r Fas III. Pirepemat (IRL752), befinner sig f\u00f6r n\u00e4rvarande i Fas IIb, och utv\u00e4rderas f\u00f6r sin effekt p\u00e5 fallfrekvens vid Parkinson. IRL757, en substans som utvecklas f\u00f6r behandling av apati vid neurodegenerativa sjukdomar, befinner sig i Fas Ib. Dessutom utvecklar bolaget de tv\u00e5 prekliniska programmen IRL942 och IRL1117 mot Fas I-studier. IRLAB:s pipeline har genererats av bolagets egenutvecklade systembiologibaserade forskningsplattform Integrative Screening Process (ISP). IRLAB har sitt huvudkontor i Sverige och \u00e4r noterat p\u00e5 Nasdaq Stockholm (IRLAB A). F\u00f6r mer information, bes\u00f6k\u00a0www.irlab.se<\/a>.<\/p>\n<\/div>\n

\n

Bifogade filer<\/strong><\/p>\n

\n

IRLAB presenterar p\u00e5 Redeye Theme: Neurology<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

G\u00f6teborg, den 9 oktober 2026 \u2014 IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), ett bolag som uppt\u00e4cker och utvecklar nya behandlingar f\u00f6r Parkinsons sjukdom, meddelar idag att vd Kristina Torfg\u00e5rd kommer att presentera IRLAB vid Redeye: Theme Neurology den 15 oktober i Stockholm.<\/p>\n","protected":false},"template":"","class_list":["post-13636","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-ci-other_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"\nIRLAB presenterar p\u00e5 Redeye Theme: Neurology - IRLAB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/irlab.se\/sv\/mfn_news\/irlab-presenterar-pa-redeye-theme-neurology-2\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IRLAB presenterar p\u00e5 Redeye Theme: Neurology - IRLAB\" \/>\n<meta property=\"og:description\" content=\"G\u00f6teborg, den 9 oktober 2026 \u2014 IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), ett bolag som uppt\u00e4cker och utvecklar nya behandlingar f\u00f6r Parkinsons sjukdom, meddelar idag att vd Kristina Torfg\u00e5rd kommer att presentera IRLAB vid Redeye: Theme Neurology den 15 oktober i Stockholm.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/irlab.se\/sv\/mfn_news\/irlab-presenterar-pa-redeye-theme-neurology-2\/\" \/>\n<meta property=\"og:site_name\" content=\"IRLAB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/irlab.se\\\/sv\\\/mfn_news\\\/irlab-presenterar-pa-redeye-theme-neurology-2\\\/\",\"url\":\"https:\\\/\\\/irlab.se\\\/sv\\\/mfn_news\\\/irlab-presenterar-pa-redeye-theme-neurology-2\\\/\",\"name\":\"IRLAB presenterar p\u00e5 Redeye Theme: Neurology - IRLAB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/irlab.se\\\/#website\"},\"datePublished\":\"2026-10-09T05:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/irlab.se\\\/sv\\\/mfn_news\\\/irlab-presenterar-pa-redeye-theme-neurology-2\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/irlab.se\\\/sv\\\/mfn_news\\\/irlab-presenterar-pa-redeye-theme-neurology-2\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/irlab.se\\\/sv\\\/mfn_news\\\/irlab-presenterar-pa-redeye-theme-neurology-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/irlab.se\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\\\/\\\/irlab.se\\\/sv\\\/pressmeddelanden\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"IRLAB presenterar p\u00e5 Redeye Theme: Neurology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/irlab.se\\\/#website\",\"url\":\"https:\\\/\\\/irlab.se\\\/\",\"name\":\"Irlab\",\"description\":\"Novel treatments for Parkinson's disease\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/irlab.se\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IRLAB presenterar p\u00e5 Redeye Theme: Neurology - IRLAB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/irlab.se\/sv\/mfn_news\/irlab-presenterar-pa-redeye-theme-neurology-2\/","og_locale":"sv_SE","og_type":"article","og_title":"IRLAB presenterar p\u00e5 Redeye Theme: Neurology - IRLAB","og_description":"G\u00f6teborg, den 9 oktober 2026 \u2014 IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), ett bolag som uppt\u00e4cker och utvecklar nya behandlingar f\u00f6r Parkinsons sjukdom, meddelar idag att vd Kristina Torfg\u00e5rd kommer att presentera IRLAB vid Redeye: Theme Neurology den 15 oktober i Stockholm.","og_url":"https:\/\/irlab.se\/sv\/mfn_news\/irlab-presenterar-pa-redeye-theme-neurology-2\/","og_site_name":"IRLAB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"1 minut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/irlab.se\/sv\/mfn_news\/irlab-presenterar-pa-redeye-theme-neurology-2\/","url":"https:\/\/irlab.se\/sv\/mfn_news\/irlab-presenterar-pa-redeye-theme-neurology-2\/","name":"IRLAB presenterar p\u00e5 Redeye Theme: Neurology - IRLAB","isPartOf":{"@id":"https:\/\/irlab.se\/#website"},"datePublished":"2026-10-09T05:00:00+00:00","breadcrumb":{"@id":"https:\/\/irlab.se\/sv\/mfn_news\/irlab-presenterar-pa-redeye-theme-neurology-2\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/irlab.se\/sv\/mfn_news\/irlab-presenterar-pa-redeye-theme-neurology-2\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/irlab.se\/sv\/mfn_news\/irlab-presenterar-pa-redeye-theme-neurology-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/irlab.se\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/irlab.se\/sv\/pressmeddelanden\/"},{"@type":"ListItem","position":3,"name":"IRLAB presenterar p\u00e5 Redeye Theme: Neurology"}]},{"@type":"WebSite","@id":"https:\/\/irlab.se\/#website","url":"https:\/\/irlab.se\/","name":"Irlab","description":"Novel treatments for Parkinson's disease","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/irlab.se\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"}]}},"_links":{"self":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/mfn_news\/13636","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/media?parent=13636"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}